Related Experiment Video
Updated: Sep 4, 2025

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)
Published on: June 27, 2025
Contribution of TLR4 to colorectal tumor microenvironment, etiology and prognosis
Elise E Crame1, Saeed Nourmohammadi2, Hannah R Wardill2,3
1Discipline of Physiology, School of Biomedicine, The University of Adelaide, Level 2 Helen Mayo South, North Terrace, Adelaide, SA, 5000, Australia. elise.crame@adelaide.edu.au.
Purpose:
Toll-like receptor 4 (TLR4) is increasingly recognized for its ability to govern the etiology and prognostic outcomes of colorectal cancer (CRC) due to its profound immunomodulatory capacity. Despite widespread interest in TLR4 and CRC, no clear analysis of current literature and data exists. Therefore, translational advances have failed to move beyond conceptual ideas and suggestions.
Methods:
We aimed to determine the relationship between TLR4 and CRC through a systematic review and analysis of published literature and datasets. Data were extracted from nine studies that reported survival, CRC staging and tumor progression data in relation to TLR4 expression. Primary and metastatic tumor samples with associated clinical data were identified through the Cancer Genome Atlas (TCGA) database.
Results:
Systematic review identified heterogeneous relationships between TLR4 and CRC traits, with no clear theme evident across studies. A total of 448 datasets were identified through the TCGA database. Analysis of TCGA datasets revealed TLR4 mRNA expression is decreased in advanced CRC stages (P < 0.05 for normal vs Stage II, Stage III and Stage IV). Stage-dependent impact of TLR4 expression on survival outcomes were also found, with high TLR4 expression associated with poorer prognosis (stage I vs III (HR = 4.2, P = 0.008) and stage I vs IV (HR = 11.3, P < 0.001)).
Conclusion:
While TLR4 mRNA expression aligned with CRC staging, it appeared to heterogeneously regulate survival outcomes depending on the stage of disease. This underscores the complex relationship between TLR4 and CRC, with unique impacts dependent on disease stage.
Insights
Toll-like receptor 4 (TLR4) expression decreases in advanced colorectal cancer (CRC) stages. While its expression correlates with CRC staging, TLR4 impacts survival outcomes differently depending on the disease stage.
Area of Science:
- Immunology
- Oncology
- Genomics
Background:
- Toll-like receptor 4 (TLR4) plays a crucial role in the immune system and is increasingly recognized for its influence on colorectal cancer (CRC) development and prognosis.
- Despite significant interest, a clear understanding of the literature and data regarding TLR4's role in CRC is lacking, hindering translational advancements.
Approach:
- A systematic review and analysis of published literature and datasets were conducted to investigate the relationship between TLR4 and CRC.
- Data from nine studies on survival, CRC staging, and tumor progression in relation to TLR4 expression were extracted.
- The Cancer Genome Atlas (TCGA) database was utilized to identify primary and metastatic tumor samples with associated clinical data.
Key Points:
- Systematic review revealed heterogeneous associations between TLR4 and CRC characteristics.
- Analysis of 448 TCGA datasets showed decreased TLR4 mRNA expression in advanced CRC stages (Stage II, III, and IV) compared to normal tissue.
- High TLR4 expression was linked to poorer prognosis in later stages of CRC (Stage III and IV).
Conclusions:
- TLR4 mRNA expression levels correlate with CRC staging.
- The impact of TLR4 on survival outcomes is complex and stage-dependent, highlighting its unique role in different phases of colorectal cancer.
More Related Videos
Related Concept Videos
The Tumor Microenvironment
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

